Yue Ji

Yue Ji

Auto-generated profile, based on publicly available information

Yue Ji

Institute of Nephrology & Beijing Key Laboratory, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing, China, bucm.edu.cn

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Medicine
Verified
Journal Article
Open access
QMQingxi Meng
Qingxi Meng
JYJi Yue
Ji Yue
MSMingfu Shang
Mingfu Shang
QSQunqun Shan
Qunqun Shan
JQJian Qi
Jian Qi
WWWeiguo Wang
Weiguo Wang
Single nucleotide polymorphisms (SNPs) at the glucose transporter 9 (GLUT9) locus are clearly related to uric acid concentrations previously identified as a major cause of gout. Due to the important function of various SNPs, we hypothesized that the common GLUT9 polymorphisms (rs16890979, rs6855911, and rs7442295) are associated with gout risk. The purpose of this investigation was to test the hypothesis.Gout risk was estimated by calculating odds ratios and 95% confidence intervals (ORs and 95% CIs). Either the fixed- or the random-effect model was used for OR calculations. Subgroup analyses were carried out by ethnicity for rs16890979 and by gender for all SNPs.We analyzed a total of 8 studies involving 2525 subjects for rs16890979, 2654 for rs6855911, and 2637 for rs7442295. A significantly declined risk was suggested in the meta-analyses of rs16890979 under dominant model (OR = 0.44, 95% CI = 0.34-0.58) and heterozygote model (OR = 0.44, 95% CI = 0.33-0.59). The OR was 0.41 under allele frequency model (OR = 0.41, 95% CI = 0.33-0.53). Significantly declined risk in relation to rs16890979 was also found among Asians. Similarly decreased risk was revealed for rs7442295, both in total samples and in males. However, the meta-analysis of rs6855911 revealed no significant associations.These data seem to support the hypothesis that the risk of gout may be associated with GLUT9 rs16890979 and rs7442295.

30 October 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
HZHe Zhu
He Zhu
YXYunming Xiao
Yunming Xiao
YJYue Ji
Yue Ji
Background: Chinese herbal medicines have been extensively used to treat idiopathic membranous nephropathy (IMN). However, their efficacy and safety remain uncertain. Therefore, this study employed a network meta-analysis to evaluate the efficacy and safety of various Chinese herbal medicines in combination with biomedicines for treating IMN.Methods: A comprehensive literature search was performed across several databases, including PubMed, EMBASE, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), WanFang Data, VIP Database, and Chinese Biomedical Literature Database (CBM), to identify randomized controlled trials (RCTs) concerning the treatment of IMN using a combination of Chinese herbal medicines and biomedicine, up to 31 May 2024. Two researchers independently conducted the literature screening and data extraction. The quality of the included studies was assessed using the Cochrane quality review manual, and Stata 14.2 software was employed for network meta-analysis.Results: A total of 31 RCTs involving 2195 IMN patients and 15 different Chinese herbal medicines were analyzed. The network meta-analysis revealed that QQC + BM (84.7%) was the most effective in reducing 24-hour urinary protein. For improving serum albumin, HZC + BM (86%) was the most effective. LGT + BM (77.2%) was the best for enhancing serum creatinine levels. MXC + BM demonstrated the highest effectiveness in lowering total cholesterol (89%) and triglycerides (97%). Lastly, WZC + BM (90.8%) was the most effective in reducing the incidence of adverse reactions. BM.Conclusion: The current evidence suggests that integrating Chinese herbal medicines with biomedicine may provide significant benefits in treating IMN. Specifically, QQC + BM appears to be the most effective in reducing 24-hour urinary protein, HZC + BM seems to excel in improving serum albumin levels, MXC + BM is noted for its effectiveness in lowering triglycerides and total cholesterol, LGT + BM is optimal for reducing serum creatinine, and WZC + BM shows the lowest rate of adverse reactions. Nevertheless, due to limitations in the quantity and quality of the included studies, further validation of these conclusions is necessary.Systematic Review Registration: [https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024561028], identifier [CRD42024561028].

15 January 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BFBaohui Fu
Baohui Fu
YJYue Ji
Yue Ji
SHShouci Hu
Shouci Hu
TRTong Ren
Tong Ren
MBMaheshkumar Satishkumar Bhuva
Maheshkumar Satishkumar Bhuva
HYHongtao Yang
Hongtao Yang
To assess the potency of anti-viral treatment for hepatitis B virus-associated glomerulonephritis (HBV-GN). Method: We searched for controlled clinical trials on anti-viral therapy for HBV-GN in MEDLINE, Embase, the Cochrane Library, and PubMed from inception to March 11th 2019. Seven trials, including 182 patients met the criteria for evaluating. The primary outcome measures were proteinuria and changes in the estimated glomerular filtration rate, and the secondary outcome measure was hepatitis B e-antigen clearance. A fixed or random effect model was established to analyze the data. Subgroup analyses were performed to explore the effects of clinical trial type, anti-viral drug type, age, and follow-up duration. The total remission rate of proteinuria (OR = 10.48, 95% CI: 4.60−23.89, I2 = 0%), complete remission rate of proteinuria (OR = 11.64, 95% CI: 5.17−26.21, I2 = 23%) and clearance rate of Hepatitis Be Antigen (HBeAg) were significantly higher in the anti-viral treatment group than in the control group (OR = 27.08, 95% CI: 3.71−197.88, I2 = 63%). However, antiviral therapy was not as effective regarding the eGFR (MD = 5.74, 95% CI: -4.24−15.73). In the subgroup analysis, age and drug type had significant impacts on proteinuria remission, and study type and follow-up duration only slightly affected the heterogeneity. Antiviral therapy induced remission of proteinuria and increased HBeAg clearance but failed to improve the eGFR. Pediatric patients were more sensitive to antiviral therapy than adults. IFNs seem more effective but are accompanied by more adverse reactions than NAs.

1 January 2026 in Journal of Diabetes Research
Verified
Journal Article
Open access
YJYue Ji
Yue Ji
YWYuqi Wu
Yuqi Wu
JTJingyi Tang
Jingyi Tang
YLYachun Li
Yachun Li
XGXi Guo
Xi Guo
WLWei Jing Liu
Wei Jing Liu
Background: Diabetic nephropathy is a leading complication of diabetes mellitus and poses a significant public health challenge. Ferroptosis has emerged as a critical pathological factor that exacerbates the progression of diabetic nephropathy. While previous studies have demonstrated the antiferroptotic effects of curcumol (Cur), its therapeutic potential in treating diabetic nephropathy, along with the underlying mechanisms, remains to be fully elucidated. Methods: To investigate this, we established a high glucose‐induced MPC‐5 cell injury model. Initially, we identified the safe concentration range of curcumol. Using Western blot (WB) analysis and transcriptomic profiling, we assessed target proteins and regulatory pathways, and systematically measured ferroptosis‐related biomarkers. To further explore Cur′s effect on ferroptosis, we cotreated the in vitro model with the ferroptosis inhibitor Fer‐1 and activator RLS3, analyzing the key pathways involved using WB and transcriptomic approaches. Additionally, we established a diabetic kidney disease (DKD) mouse model to assess the effects of Cur on renal function indicators, including serum creatinine, urea nitrogen, and 24‐h urinary protein levels. Renal pathological changes and molecular markers were evaluated, and the core pathway mechanisms were validated by WB analysis. Results: In in vitro experiments, Cur reduced iron deposition and total iron content by downregulating TRF and NCOA4. It also inhibited ACSL4‐mediated lipid peroxidation, resulting in lower levels of ROS, MDA, and 4‐HNE. Additionally, Cur upregulated the expression of SLC3A2, SLC7A11, and GPX4, thereby restoring the GSH‐GPX4 antioxidant system. In vivo, Cur improved renal function and alleviated renal injury in DKD mice through the xCT/GPX4 signaling pathway. These findings suggest that Cur mitigates ferroptosis via the xCT/GPX4 pathway, ultimately slowing the progression of diabetic kidney disease. Conclusion: Our in vitro and in vivo experiments demonstrate that Cur has therapeutic potential for DKD. Mechanistically, Cur protects against podocyte ferroptosis by modulating the xCT/GPX4 pathway.

2 December 2022 in Medicine
Verified
Journal Article
Open access
YGYuancheng Mm Gao
Yuancheng Mm Gao
YJYue Ji
Yue Ji
YSYulin Mb Song
Yulin Mb Song
RGRui Mb Gong
Rui Mb Gong
CCCheng Mb Chen
Cheng Mb Chen
HCHongbo Chen
Hongbo Chen
Background: Type 2 diabetic kidney disease (DKD) is one of the most common and harmful chronic complications in clinical practice, and there is no reliable and targeted treatment plan at present. As a classic complementary and alternative therapy, evidence have shown that warm acupuncture has advantages in the treatment of type 2 DKD. However, there is still a lack of high-quality and long-term follow-up randomized controlled trials of warm acupuncture in the treatment of type 2 DKD. Methods: This is a prospective randomized controlled trial to investigate the efficacy and safety of warm acupuncture in the treatment of type 2 DKD. Participants will be randomly assigned in a 1:1 ratio to either the treatment group (treated with conventional Western medicine) or the control group (treated with warm acupuncture added on the basis of the control group). Both groups will receive 12 weeks of treatment followed by 24 weeks of follow-up. Observation indicators include: 24-hour urinary protein quantification, kidney function, TCM syndrome score and adverse reactions. Finally, SPSS21.0 software will be used to analyze the data. Discussion: This study will evaluate the efficacy and safety of warm acupuncture in the treatment of DKD, and the results of this trial will provide clinical evidence for the treatment of type 2 DKD. Trial registration: The TCTR identification number is TCTR20221104004.

6 April 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
JLJin Lin
Jin Lin
YJYue Ji
Yue Ji
JSJinhua Si
Jinhua Si
GWGuanran Wang
Guanran Wang
XLXinju Li
Xinju Li
LSLi Shen
Li Shen
Objective. Xiaoyao San (XYS) is a medicinal preparation that is commonly employed in China for the treatment of anxiety disorders (AD). Despite suggestions that it may offer certain advantages in this context, there are no reliable evidence-based studies regarding its efficacy at present. The present study was developed to gauge the efficacy and safety of XYS for the treatment of AD in a systematic manner. Methods. PubMed, the Cochrane Library, EMBASE, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang database, Weipu database, and China Biomedical Documentation Service System (CBM) databases were systematically searched for all randomized control trials (RCTs) evaluating the use of XYS for the treatment of AD published as of November 2021. Two investigators independently screened all studies, extracted data, and assessed the risk of bias for included studies using RevMan5.3. Results. In total, 9 RCTs incorporating 809 patients were included in the present meta-analysis, of which 3 compared oral XYS to anxiolytic treatment and 6 compared oral XYS+anxiolytics to anxiolytic treatment alone. The resultant meta-analysis revealed that XYS alone or in combination with anxiolytic treatment was associated with better improvements in anxiety-related symptoms and reduced adverse drug-related reactions as compared to anxiolytic treatment alone. Conclusion. The available evidence suggests that oral XYS alone or in combination with anxiolytic agents is more effective and safer than anxiolytic treatment alone when used for the treatment of AD. However, owing to the limited number and quality of the studies included in this analysis, further high-quality research will be essential to validate these results.